Serine

What is Serine?

L-Serine is a conditionally essential amino acid naturally synthesized in the human body from 3-phosphoglycerate, a glycolytic intermediate, primarily in astrocytes in the brain. It is classified as conditionally essential because synthesis may be insufficient under high metabolic demand, neurological disease, or certain genetic enzyme deficiencies (e.g., 3-phosphoglycerate dehydrogenase deficiency). Beyond its role as a protein building block, serine functions as a metabolic hub, feeding into one-carbon metabolism, de novo sphingolipid synthesis, and phospholipid production.

How does Serine work?

L-Serine exerts its neurological effects primarily through two downstream pathways: conversion to D-serine (via serine racemase), which acts as a co-agonist at NMDA glutamate receptors and is essential for synaptic plasticity and memory consolidation; and conversion to phosphatidylserine and sphingomyelin, which are structural phospholipids critical for neuronal membrane integrity and signaling. Serine also contributes to the folate one-carbon cycle, supporting methylation reactions that regulate gene expression and neurotransmitter synthesis. Deficiency in brain serine supply has been linked to dysregulation of D-serine signaling and aberrant sphingolipid accumulation, both implicated in neurodegenerative disease.

What forms does Serine come in?

L-Serine is most commonly available as a free-form amino acid powder or capsule. Powder form allows flexible dosing and is well absorbed orally. In clinical research settings, particularly ALS and rare pediatric neurological disorders, intravenous administration has been studied. Phosphatidylserine supplements (derived from soy or sunflower lecithin) are a related but distinct product that provides serine in a phospholipid-bound form rather than as free amino acid.

Where it comes from:

Interest in supplemental L-Serine grew substantially after epidemiological research in the 1990s–2000s linked high dietary exposure to the cyanobacterial toxin BMAA (beta-methylamino-L-alanine) — which competes with L-Serine — to elevated rates of ALS-parkinsonism-dementia complex in Guam. This led to investigation of L-Serine supplementation as a potential neuroprotective intervention in ALS and related conditions. Separately, inherited disorders of serine biosynthesis (Neu-Laxova syndrome, 3-PGDH deficiency) established that adequate serine is essential for normal brain development, lending mechanistic credibility to supplementation research.

What does Serine help with?

• ALS — Neuroprotection (Investigational): The proposed mechanism is that L-Serine competes with the environmental neurotoxin BMAA for incorporation into proteins, reducing misfolded protein accumulation in motor neurons. In a Phase I randomized, double-blind, placebo-controlled trial (Stommel et al., 2021, Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, n=20), L-Serine at 15 g/day and 30 g/day was found to be safe and well tolerated in ALS patients, with preliminary signals suggesting slower functional decline on the ALS Functional Rating Scale-Revised (ALSFRS-R) at the higher dose, though the trial was underpowered to confirm efficacy. A larger Phase II trial (SERINE-ALS) has been conducted to further evaluate these signals, with results contributing to the growing evidence base.
• Hereditary Sensory and Autonomic Neuropathy Type 1 (HSAN1): HSAN1 is caused by mutations in serine palmitoyltransferase (SPT) that cause the enzyme to use alanine or glycine instead of serine as a substrate, producing neurotoxic deoxy-sphingolipids. Supplemental L-Serine corrects this metabolic error by flooding the SPT enzyme with its correct substrate, competitively reducing deoxy-sphingolipid synthesis. A randomized, double-blind, placebo-controlled crossover trial (Fridman et al., 2019, Neurology, n=18) demonstrated that oral L-Serine (400 mg/kg/day) significantly reduced plasma 1-deoxysphingolipid levels and showed positive trends in neuropathy symptom scores, representing one of the strongest mechanistically grounded human RCTs for L-Serine supplementation.
• Cognitive Function and Memory: L-Serine supports cognitive function primarily through its conversion to D-serine, the endogenous co-agonist at NMDA receptors in the hippocampus and prefrontal cortex, regions critical for learning and memory consolidation. Additionally, serine is a phosphatidylserine precursor, and brain phosphatidylserine supports neuronal membrane fluidity and signaling. Clinical evidence for L-Serine supplementation specifically in cognition is limited; most robust cognitive data comes from phosphatidylserine RCTs (e.g., Cenacchi et al., 1993, Aging: Clinical and Experimental Research, n=494), which provide mechanistically linked but not directly equivalent evidence for supplemental L-Serine.
• Sleep Quality: L-Serine has been investigated for sleep support based on its role in glycine synthesis (glycine itself improves sleep quality in human RCTs) and its modulatory effects on NMDA receptor activity, which influences sleep architecture. A small placebo-controlled trial conducted in Japan (Ono et al., 2012, Neuropsychopharmacology Reports — note: verify exact journal name in admin) found that oral L-Serine supplementation before bed improved subjective sleep quality and reduced sleep-onset latency in adults with mild sleep complaints. The evidence base is modest and replication in larger samples is needed.
• Childhood Serine Biosynthesis Disorders (3-PGDH Deficiency): Children with inborn errors of serine biosynthesis (3-phosphoglycerate dehydrogenase deficiency) present with severe neurological deficits, microcephaly, and seizures. Oral L-Serine supplementation (up to 600 mg/kg/day) has been shown in case series and small clinical studies to dramatically reduce seizure frequency and improve developmental outcomes when started early, representing a compelling example of the amino acid's critical role in brain development. This is arguably the most robust human evidence for L-Serine's neurological necessity, though the patient population is rare.

What can Serine help prevent?

• Deoxy-sphingolipid accumulation in HSAN1 mutation carriers (evidence from Fridman et al., 2019 RCT)

Which foods are rich in Serine?

1. Soy protein / Edamame: Soy protein is among the highest dietary sources of L-Serine by amino acid composition, with roughly 5–6 g of serine per 100 g of protein, making it a practical whole-food source.
2. Eggs (egg white): Egg whites contain substantial serine (~9 g serine per 100 g protein), and are a highly bioavailable complete protein source readily accessible in most diets.
3. Meat (beef, chicken, turkey): Animal proteins, particularly lean beef and poultry, provide serine at 4–5 g per 100 g protein and are complete protein sources with high bioavailability.
4. Dairy (cottage cheese, Greek yogurt): Casein and whey proteins found in dairy contain meaningful amounts of serine and also provide phosphatidylserine precursors, supporting both direct serine intake and downstream phospholipid synthesis.
5. Nuts and seeds (peanuts, sesame, sunflower seeds): Nuts and seeds are moderate plant-based sources of serine and also provide phosphatidylserine-rich lipid fractions, supporting serine-dependent neurological pathways from multiple angles.

Practical Tips:

L-Serine is naturally present in all protein-containing foods as a component of protein chains. Dietary protein from varied sources (animal and plant) generally provides adequate serine for healthy individuals. Therapeutic supplementation at doses used in clinical trials (e.g., 15–30 g/day in ALS research) substantially exceeds what is achievable through diet alone.

What are the side effects of Serine?

• Nausea or gastrointestinal discomfort (most common, dose-dependent)
• Loose stools or diarrhea at high doses (>15 g/day)
• Mild sedation or fatigue (reported anecdotally, possibly via glycine conversion)
• Headache (rare, not consistently documented across trials)
• Theoretical risk of exacerbating certain metabolic disorders involving serine catabolism (relevant only in specific enzyme deficiencies)

Good to know:

L-Serine is generally well tolerated across the dose ranges studied in human clinical trials (up to 30 g/day in ALS trials). At very high doses, gastrointestinal side effects are the most commonly reported adverse events. Serine is a natural constituent of dietary protein and has a long history of human consumption through food.

How much Serine should you take?

• Recommended daily: General cognitive/neurological support: 3–7 g/day in divided doses. HSAN1 (therapeutic, under medical supervision): 400 mg/kg/day. ALS clinical trial dosing: 15–30 g/day (medical supervision required). Childhood serine biosynthesis disorders: up to 600 mg/kg/day (specialist-directed).
• Best time of day: Divide doses across 2–3 times daily to maintain steady plasma levels. For sleep support, some evidence supports taking a portion of the dose (1–3 g) 30–60 minutes before bedtime, consistent with glycine-pathway research.
• With or without food: Can be taken with or without food. Taking with a small meal or protein-containing snack may improve tolerability and reduce gastrointestinal discomfort at higher doses.
• Time to effect: Metabolic markers (e.g., deoxy-sphingolipid reduction in HSAN1) may normalize within 4–8 weeks. Cognitive and sleep benefits, where reported, typically emerge after 2–4 weeks of consistent use. Neuroprotective effects in progressive disease may require months to assess.
• How long to take it: For therapeutic conditions (HSAN1, ALS), long-term continuous use under physician supervision is standard. For general cognitive support, a 3-month trial is reasonable to assess benefit; no established cycling protocol is required, but periodic reassessment is advisable.